Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring <i>MET</i> exon 14 mutation: a research report.

ABSTRACT: Tyrosine kinase inhibitors (TKIs) have transformed the standard of care in lung cancer. A number of TKIs have been discovered that specifically target oncogenes, including MET receptor tyrosine kinase. Second-generation MET TKIs are showing improved efficacy over first-generation TKIs. Herein, we report a case of a patient with metastatic lung adenocarcinoma harboring a MET exon 14 splice site mutation who has had prolonged disease control by a second-generation MET-TKI tepotinib. A 66-yr-old man was diagnosed with stage IV lung adenocarcinoma. He was started on carboplatin, paclitaxel, and bevacizumab, but had severe toxicity. He was switched to pembrolizumab as his tumor was PD-L1 70%, and molecular testing was not yet performed because of insufficient tissue. A bronchoscopy with

SUBMITTER: Roth KG 

PROVIDER: S-EPMC7784494 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature